Forward Pharma Loses Appeal in Tecfidera Patent Dispute With Biogen

By REUTERS
NYT
A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.
Published date: October 24, 2018 at 06:26PM
Reuters
New York Times article